| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 5 Nov 2025 | 29 Oct 2025 |
| Caplin Point Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2025 ,inter alia, to consider and approve unaudited financial results of the Company for the quarter and half-year ended September 30, 2025. Caplin Point Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2025 ,inter alia, to consider and approve the unaudited financial results of the Company for the quarter and half-year ended September 30, 2025 Outcome of the Board Meeting Un-audited standalone and consolidated financial results for the quarter and half year ended 30th September 2025 (As Per BSE Announcement Dated on:05.11.2025) | ||
| Board Meeting | 7 Aug 2025 | 30 Jul 2025 |
| Caplin Point Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2025 inter alia to consider and approve 1) Quarterly unaudited financial results for the quarter ended June 30 2025 (both standalone & consolidated); 2) Recommendation of Final Dividend for the FY 2024-25 for approval of shareholders; 3) Convening the Annual General Meeting of the Company; and 4) Fixation of record date for determining the eligibility of shareholders entitled for the Final Dividend. Outcome of the Board Meeting held on August 7, 2025 (As Per BSE Announcement Dated on:07.08.2025) | ||
| Board Meeting | 15 May 2025 | 7 May 2025 |
| Caplin Point Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/05/2025 inter alia to consider and approve Annual audited financial results of the Company for the year ended March 31 2025 (both standalone & consolidated) and declaration of Interim Dividend if any for the FY 2024-25 and fixation of record date for determining the eligibility of shareholders. The Board had approved interim dividend for the year ended 31-03-2025 along with the audited results. The details of the same is enclosed herewith. (As Per BSE Announcement Dated on:15.05.2025) | ||
| Board Meeting | 7 Feb 2025 | 31 Jan 2025 |
| CAPLIN POINT LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2025 inter alia to consider and approve The un-audited financial results of the Company for the quarter and nine months ended December 31 2024 (both standalone & consolidated) Financial Results along with the Limited Review Report, Press Release and Investor PPT for the quarter ended December 31, 2024 is enclosed (As Per BSE Announcement Dated on: 07/02/2025) | ||
The drug is the generic alternative of the Vitamin K1 Injection produced by Hospira Inc and is indicated in the treatment of Vitamin K deficiency-related coagulation disorders.
Here are some of the stocks that may see significant price movement today: ICICI Prudential, Caplin Point, Ashoka Buildcon, etc.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
